Gilead Sciences
FOSTER CITY, CAfiles as GILEAD SCIENCES, INC.
$1.6bn in 5 US stocks at the end of 30 June 2026. The top 10 are 100.0% of the money. It changed about 36.4% of the portfolio this quarter.
Value
$1.6bn
Stocks
5
Top 10 share
100.0%
Turnover
36.4%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
- Assembly BiosciencesASMB8.3% of the fund+10%
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
- Arcellx-100%
Holdings
- Lakefront Biotherapeutics NVLKFT
- Share
- 30.3%
- Value
- $500m
- Shares
- 16,707,477
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Arcus BiosciencesRCUS | 58.8% | $969m | 31,424,760 | Held |
| Lakefront Biotherapeutics NVLKFT | 30.3% | $500m | 16,707,477 | Held |
| Assembly BiosciencesASMB | 8.3% | $137m | 4,977,089 | +10% |
| Kyverna TherapeuticsKYTX | 2.2% | $37m | 4,126,119 | Held |
| Xilio TherapeuticsXLO | 0.4% | $6m | 650,389 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 28.8% since 30 June 2025.
Where the money is
Health care69.7%
Other30.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.